Company: PCRX
Filing Date: 2025-11-06
Form Type: 10-Q
Source: 0001628280-25-050176
Chunk: 48

Company: Pacira BioSciences, Inc.
Filing Date: 2025-11-06
Form: 10-Q
Item: Part I, Item 1
Chunk 48
---
 38,905 Changes in contingent consideration(2,407)(5,541)Other net gains(5,887)(53)Changes in operating assets and liabilities:  Accounts receivable, net(1,943)4,903 Inventories, net(32,384)(7,512)Prepaid expenses and other assets(13,911)(6,338)Accounts payable(2,669)3,409 Accrued expenses and income taxes payable(7,145)12,546 Other liabilities5,079 (1,195)Net cash provided by operating activities108,305 156,257 Investing activities:  Acquisition of GQ Bio Therapeutics GmbH (net of cash acquired)(16,702)— Purchases of fixed assets(15,115)(8,518)Purchases of available-for-sale investments(113,450)(207,017)Sales of available-for-sale investments226,665 132,627 Purchases of debt investments(1,250)— Net cash provided by (used in) investing activities80,148 (82,908)Financing activities:  Proceeds from exercises of stock options12 — Proceeds from shares issued under employee stock purchase plan1,569 1,364 Payment of employee withholding taxes on restricted stock unit vests(5,474)(414)Purchase of treasury stock, inclusive of broker fees(100,080)(25,000)Proceeds from 2029 convertible senior notes— 287,500 Proceeds from Revolving Credit Facility101,000 — Repayment of 2024 convertible senior notes— (8,641)Repayment of 2025 convertible senior notes(202,487)(190,994)Repayment of Term loan A facility(105,312)(8,438)Repayment of Revolving Credit Facility(5,000)— Purchase of capped call transactions— (26,709)Payment of debt issuance and financing costs(2,203)(9,350)Net cash (used in) provided by financing activities(317,975)19,318 Effect of exchange rate changes on cash and cash equivalents337 — Net (decrease) increase in cash and cash equivalents(129,185)92,667 Cash and cash equivalents, beginning of period276,774 153,298 Cash and cash equivalents, end of period$147,589 $245,965 See accompanying condensed